Results 131 to 140 of about 74,688 (254)

Impact of Dental Status on Heart Transplantation Outcomes

Oral Diseases, EarlyView.
ABSTRACT Objective Oral infections and poor dental health may contribute to systemic complications after heart transplantation, yet data on their impact is limited. In the absence of standardized dental guidelines for transplant candidates, this study evaluated preoperative dental status and its association with post‐transplant outcomes.
Katharina Theresa Obermeier, Ina Dewenter, Maximilian Vorstandlechner, Maximilian Geyer, Wenko Smolka, Christine Kamla, Madeleine Orban, Christoph S. Mueller, Anusha Abdullah   +8 more
wiley   +1 more source

Drug-Induced Liver Injury Associated with the Use of Everolimus in a Liver Transplant Patient

Case Reports in Transplantation, 2018
Drug-induced liver injury (DILI) has not been previously reported as a complication of treatment with everolimus. A 56-year-old Caucasian male liver transplant recipient developed DILI after receiving everolimus.
Serena Patel, Michel H. Mendler, Mark A. Valasek, Shirley M. Tsunoda   +3 more
doaj   +1 more source

Long-term forecasting and comparison of mortality in the Evaluation of the Xience Everolimus Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial: prospective validation of the SYNTAX Score II [PDF]

, 2015
Carlos M. Campos, David van Klaveren, Vasim Farooq, Charles A. Simonton, A. Pieter Kappetein, Joseph F. Sabik, Ewout W. Steyerberg, Gregg W. Stone, Patrick W. Serruys, the EXCEL Trial Investigators   +9 more
openalex   +1 more source

Supplementary Figure Legend from Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia

, 2023
Aldo M. Roccaro, Antonio Sacco, Xiaojing Jia, Ranjit Banwait, Patricia Maiso, Feda Azab, Ludmila M. Flores, Salomon Manier, Abdel Kareem Azab, Irene M. Ghobrial   +9 more
openalex   +1 more source

Role of BK Virus CTLs in the Treatment of BK Virus–Associated Nephropathy in Kidney‐Transplant and Hematopoietic Cell Transplant Recipients

Transplant Infectious Disease, EarlyView.
Third‐party, BK virus‐specific cytotoxic T lymphocytes (CTLs) were safe and effective in reducing viremia in kidney and stem cell transplant recipients with BK virus nephropathy. However, they did not improve kidney function. Earlier administration may be more beneficial before nephropathy and irreversible damage occur.
Amanda Olson, Ye Ethan Li, Rafet Basar, Pinaki Banerjee, Indresh Kaur, Glorette Abueg, Melihate Sylejmani, Nadima Uprety, Rejeena Shrestha, Francia Reyes Silva, Valda Page, Richard E. Champlin, Dimitrios P. Kontoyiannis, Roy F. Chemaly, Elizabeth J. Shpall, Linda Moore, Osama A. Gaber, Katayoun Rezvani, Ala Abudayyeh   +18 more
wiley   +1 more source

HHV‐8/KSHV in Solid Organ Transplantation: Current Gaps of Knowledge and Future Directions

Transplant Infectious Disease, EarlyView.
Risk mitigation strategies, including donors/recipients screening, DNAemia monitoring in recipients at risk, CNI‐to‐mTOR inhibitors switch, antivirals, and rituximab for KICS, may mitigate the impact of HHV‐8/KSHV infection in SOT. This review provides an update on KICS, identifies research gaps, and summarizes advances in screening and management ...
Alessandra Mularoni, Andrea Cona, Malgorzata Mikulska, Francesca Pecoraro, Carlotta Piazza, Elda De Vita, Giada Pietrosi, Matteo Bulati, Tiziana Lazzarotto, Mario Luppi   +9 more
wiley   +1 more source

Data from Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib

, 2023
Nikhil Wagle, Brian C. Grabiner, Eliezer M. Van Allen, Eran Hodis, Susanna Jacobus, Jeffrey G. Supko, Michelle Stewart, Toni K. Choueiri, Leena Gandhi, James M. Cleary, Aymen Elfiky, Mary Ellen Taplin, Edward C. Stack, Sabina Signoretti, Massimo Loda, Geoffrey I. Shapiro, David M. Sabatini, Eric S. Lander, Stacey Gabriel, Philip W. Kantoff, Levi A. Garraway, Jonathan E. Rosenberg   +21 more
openalex   +1 more source

Reprogramming SREBP1‐dependent lipogenesis and inflammation in high‐risk breast with licochalcone A: A novel path to cancer prevention

International Journal of Cancer, Volume 158, Issue 7, Page 1927-1940, 1 April 2026.
What's new? Endocrine drugs repurposed from treatment protocols are the primary medications available for breast cancer (BC) prevention in at‐risk women. Adverse effects, however, significantly minimize uptake and prevention impact. Here, the authors investigated licochalcone A (LicA), a non‐endocrine anti‐inflammatory agent with reported hematologic ...
Atieh Hajirahimkhan, Elizabeth T. Bartom, Carolina H. Chung, Xingyu Guo, Kyli Berkley, Seyyedmohsen Hosseinibarkooie, Zahra Assadi, Shao Huan Samuel Weng, Raymond Moellering, Oukseub Lee, Ruohui Chen, Wonhwa Cho, Sriram Chandrasekaran, Susan E. Clare, Seema A. Khan   +14 more
wiley   +1 more source

Evaluation of safety and activity of everolimus plus exemestane in metastatic breast cancer: a single institution experience [PDF]

, 2015
I. Ferrarini, Ilaria Bertolini, Sara Fancelli, Claudia De Angelis, Andrea Fontana, B. Salvadori, Elisa Landucci, Andrea Michelotti, Alfredo Falcone   +8 more
openalex   +1 more source

Supplementary Figures 7-8 from The mTORC1 Inhibitor Everolimus Prevents and Treats Eμ-<i>Myc</i> Lymphoma by Restoring Oncogene-Induced Senescence

, 2023
Meaghan Wall, Gretchen Poortinga, Kym L. Stanley, Ralph K. Lindemann, Michael Bots, Christopher J. Chan, Megan J. Bywater, Kathryn M. Kinross, Megan V. Astle, Kelly Waldeck, Katherine M. Hannan, Jake Shortt, Mark J. Smyth, Scott W. Lowe, Ross D. Hannan, Richard B. Pearson, Ricky W. Johnstone, Grant A. McArthur   +17 more
openalex   +1 more source